登录 | 注册    关注公众号  
微信公众号
搜索
 > 【Integrin alpha V beta 8】

Integrin alpha V beta 8信息

英文名称:integrin alpha V/beta 8
中文名称:整合素α-v/β-8复合体
靶点别称:alphavbeta8 integrin
上市药物数量:0
临床药物数量:2
最高研发阶段:临床二期

Integrin alpha V beta 8分子别名

Integrin alpha V beta 8,ITGAV&ITGB8

Integrin alpha V beta 8分子背景

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Integrin alpha V beta 8临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
CRB-601 CRB-601 临床一期 Corbus Pharmaceuticals Holdings Inc 实体瘤 详情
Nesvategrast OTT-166(OcuTerra Therapeutics); SF-0166 临床二期 Scifluor Life Sciences Inc, OcuTerra Therapeutics Inc 糖尿病黄斑水肿, 糖尿病视网膜病变, 年龄相关性黄斑变性 详情

消息提示

请输入您的联系方式,再点击提交!

确定